LIDDS AB (publ) announced that the company has closed the on-going R&D collaboration project with Johnson & Johnson Enterprise Innovation Inc. following completion of all activities and delivery of its final report. Following the recent Joint Research Committee, at which the LIDDS team delivered their final report from the collaboration, Johnson & Johnson Enterprise Innovation Inc. communicated its decision to not continue any further development activities at this time. The collaboration was formed in 2021 with the aim to develop an oncology product based on the NanoZolid® technology for an undisclosed indication.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.16 SEK | -3.61% | -1.84% | +48.15% |
Mar. 21 | Sweden's Lidds Finalizes Purchase of Noviga Research | MT |
Mar. 21 | LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB. | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+48.15% | 2.1M | |
+8.96% | 105B | |
-1.43% | 104B | |
+5.50% | 22.94B | |
-12.15% | 22.34B | |
-6.26% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- LIDDS Stock
- News LIDDS AB
- LIDDS AB Announces Closure of R&D Project with Johnson & Johnson Enterprise Innovation Inc